Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu1928-Hu20BB CAR T Cells for B-cell Malignancies and Hodgkin Lymphoma
NCT04160195Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Hu1928-Hu20BB CAR T cells in B cell lymphoma, chronic lymphocytic leukemia (CLL) and Hodgkin lymphoma (HL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Number of Participants Who Experienced a Dose-limiting Toxicity at 28 days. Started Dec 2019; status: terminated.
02
Drugs
Hu1928-Hu20BB CAR T cells
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04160195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160195.